1887

Chapter 33 : Acquired Antibody-Mediated Immunity to Fungi

Authors: Liise-Anne Pirofski1, Arturo Casadevall2
VIEW AFFILIATIONS HIDE AFFILIATIONS
Affiliations: 1: Departments of Medicine, Microbiology, and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461; 2: Departments of Medicine, Microbiology, and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461
Content Type: Monograph
Publication Year: 2006

Category: Fungi and Fungal Pathogenesis

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Preview Magnify
Zoom in
Zoomout

Acquired Antibody-Mediated Immunity to Fungi, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815776/9781555813680_Chap33-1.gif /docserver/preview/fulltext/10.1128/9781555815776/9781555813680_Chap33-2.gif

Abstract:

The importance of antibody-mediated immunity (AMI) for resistance to fungal disease has not been rigorously examined for most clinically relevant fungi. Information from the fungi that have been studied suggests that AMI can play an immunoregulatory role. Despite uncertainty about the importance of AMI in natural resistance to fungi, the efficacy of antibody (Ab) against , , , and is now established in experimental models. The demonstration that Ab can mediate protection against these fungi provides proof of the principle that AMI can be effective against medically relevant fungi. A human monoclonal Ab (MAb) to glucuronoxylomannan (GXM) produced from lymphocytes of a volunteer GXM-tetanus toxoid (TT) recipient reacted with all four GXM serotypes, albeit better with serotypes D and A. MAbs produced from human immunoglobulin (Ig) transgenic mice were largely specific for serotype D GXM but were reactive with serotype A cells, suggesting differential expression of the epitope(s) they recognize. Proof of the principle that AMI can prolong survival and enhance host immune mechanisms against experimental cryptococcosis fueled a paradigm shift that has resulted in reconsideration of Ab-based therapies for many infectious diseases. Protective and nonprotective Abs to represent another system in which anti-fungal Abs can be distinguished by their structure and specificity and further clarifies the basis of historical difficulties in establishing the efficacy of sera against fungi.

Citation: Pirofski L, Casadevall A. 2006. Acquired Antibody-Mediated Immunity to Fungi, p 487-503. In Heitman J, Filler S, Edwards, Jr. J, Mitchell A (ed), Molecular Principles of Fungal Pathogenesis. ASM Press, Washington, DC. doi: 10.1128/9781555815776.ch33

Key Concept Ranking

Fungal Infections
0.4218488
0.4218488
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555815776.ch33
1. Abadi, J., and, L. Pirofski. 1999. Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without HIV infection. J. Infect. Dis. 180:915–919.
2. Agematsu, K.,, H. Nagumo,, K. Shinozaki,, S. Hokibara,, K. Yasui,, K. Terada,, N. Kawamura,, T. Toba,, S. Nonoyama,, H. D. Ochs, and, A. Komiyama. 1998. Absence of IgD-CD27( + ) memory B cell population in X-linked hyper-IgM syndrome. J. Clin. Investig. 102:853–860.
3. Aguirre, K. M., and, L. L. Johnson. 1997. A role for B cells in resistance to Cryptococcus neoformans in mice. Infect. Immun. 65:525–530.
4. Allendorfer, R.,, G. D. Brunner, and, G. S. Deepe, Jr. 1999. Complex requirements for nascent and memory immunity in pulmonary histoplasmosis. J. Immunol. 162:7389–7396.
5. Banerjee, U.,, K. Datta,, T. Majumdar, and, K. Gupta. 2001. Cryptococcosis in India: the awakening of a giant? Med. Mycol. 39:51–67.
6. Bartlett, M. S.,, W. C. Angus,, M. M. Shaw,, P. J. Durant,, C. H. Lee,, J. M. Pascale, and, J. W. Smith. 1998. Antibody to Pneumocystis carinii protects rats and mice from developing pneumonia. Clin. Diagn. Lab. Immunol. 5:74–77.
7. Beenhouwer, D. O.,, R. J. May,, P. Valadon, and, M. D. Scharff. 2002. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library. J. Immunol. 169:6992–6999.
8. Beenhouwer, D. O.,, S. Shapiro,, M. Feldmesser,, A. Casadevall, and, M. D. Scharff. 2001. Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans. Infect. Immun. 69:6445–6455.
9. Beenhouwer, D. O.,, P. Valadon,, R. May, and, M. D. Scharff. 2000. Peptide mimicry of the polysaccharide capsule of Cryptococcus neoformans, p. 143–160. In M. W. Cunningham and R. S. Fujinami (ed.), Molecular Mimicry: Microbes and Autoimmunity. ASM Press, Washington, D.C.
10. Berberian, L.,, L. Goodglick,, T. J. Kipps, and, J. Braun. 1993. Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science 261:1588–1591.
11. Bergmann, C. C.,, C. Ramakrishna,, M. Kornacki, and, S. A. Stohlman. 2001. Impaired T cell immunity in B cell-deficient mice following viral central nervous system infection. J. Immunol. 167:1575–1583.
12. Bot, A. 1996. Immunoglobulin deficient mice generated by gene targeting as models for studying the immune response. Int. Rev. Immunol. 13:327–340.
13. Bromuro, C.,, A. Torosantucci,, P. Chiani,, S. Conti,, L. Polonelli, and, A. Cassone. 2002. Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated candidiasis in recipients of a Candida albicans vaccine. Infect. Immun. 70:5462–5470.
14. Buchwald, U. K.,, A. Lees,, M. Steinitz, and, L. Pirofski. 2005. A peptide mimotope of type 8 pneumococcal capsular polysaccharide induces a protective immune response in mice. Infect. Immun. 73:325–333.
15. Burnie, J., and, R. Matthews. 2004. Genetically recombinant antibodies: new therapeutics against candidiasis. Expert Opin. Biol. Ther. 4:233–241.
16. Bystricky, S.,, E. Paulovicova, and, E. Machova. 2003. Candida albicans mannan-protein conjugate as vaccine candidate. Immunol. Lett. 85:251–255.
17. Caesar-TonThat, T C., and, J. E. Cutler. 1997. A monoclonal antibody to Candida albicans enhances mouse neutrophil candidacidal activity. Infect. Immun. 65:5354–5357.
18. Casadevall, A. 1995. Antibody immunity to invasive fungal infections. Infect. Immun. 63:4211–4218.
19. Casadevall, A. 2004. The methodology for determining the efficacy of antibody-mediated immunity. J. Immunol. Methods 291:1–10.
20. Casadevall, A.,, W. Cleare,, M. Feldmesser,, R. Glatman-Freedman,, T. R. Kozel,, N. Lendvai,, J. Mukherjee,, L. Pirofski,, J. Rivera,, A. L. Rosas,, M. D. Scharff,, P. Valadon,, K. Westin, and, Z. Zhong. 1998. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide which is a candidate for human therapeutic studies. Antimicrob. Agents Chemother. 42:1437–1446.
21. Casadevall, A.,, E. Dadachova, and, L. A. Pirofski. 2004. Passive antibody therapy for infectious diseases. Nat. Rev. Microbiol. 2:695–703.
22. Casadevall, A.,, M. DeShaw,, M. Fan,, F. Dromer,, T. R. Kozel, and, L. Pirofski. 1994. Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan. Infect. Immun. 62:3864–3872.
23. Casadevall, A.,, J. Mukherjee,, S. J. Devi,, R. Schneerson,, J. B. Robbins, and, M. D. Scharff. 1992. Antibodies elicited by a Cryptococcus neoformans- tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J. Infect. Dis. 165:1086–1093.
24. Casadevall, A.,, J. Mukherjee, and, M. D. Scharff. 1992. Monoclonal antibody based ELISAs for cryptococcal polysaccharide. J. Immunol. Methods 154:27–35.
25. Casadevall, A., and, L. Pirofski. 2005. Insights into mechanisms of antibody-mediated immunity from studies with Cryptococcus neoformans. Curr. Mol. Med. 5:421–433.
26. Casadevall, A., and, L. A. Pirofski. 2004. New concepts in antibody-mediated immunity. Infect. Immun. 72:6191–6196.
27. Casadevall, A.,, A. L. Rosas, and, J. D. Nosanchuk. 2000. Melanin and virulence in Cryptococcus neoformans. Curr. Opin. Microbiol. 3:354–358.
28. Casadevall, A., and, M. D. Scharff. 1994. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob. Agents Chemother. 38:1695–1702.
29. Casanova, M.,, J. P. Martinez, and, W. L. Chaffin. 1990. Fab fragments from a monoclonal antibody against a germ tube mannoprotein block the yeast-to-mycelium transition in Candida albicans. Infect. Immun. 58:3810–3812.
30. Cassone, A.,, M. Boccanera,, D. Adriani,, G. Santoni, and, F. De Bernardis. 1995. Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal reinfection. Infect. Immun. 63:2619–2624.
31. Cassone, A.,, A. Torosantucci,, M. Boccanera,, G. Pellegrini,, C. Palma, and, F. Malavasi. 1988. Production and characterisation of a monoclonal antibody to a cell-surface, glucomannoprotein constituent of Candida albi-cans and other pathogenic Candida species. J. Med. Microbiol. 27:233–238.
32. Cenci, E.,, A. Mencacci,, A. Spreca,, C. Montagnoli,, A. Bacci,, K. Perruccio,, A. Velardi,, W. Magliani,, S. Conti,, L. Polonelli, and, L. Romani. 2002. Protection of killer anti-idiotypic antibodies against early invasive aspergillosis in a murine model of allogeneic T-cell-depleted bone marrow transplantation. Infect. Immun. 70:2375–2382.
33. Chang, Q.,, P. Alpert,, J. Abadi, and, L. Pirofski. 2000. A pneumococcal capsular polysaccharide vaccine induces a repertoire shift with increased VH3 expression in peripheral B cells from HIV-uninfected, but not HIV-infected individuals. J. Infect. Dis. 181:1313–1321.
34. Chen, L. C.,, D. L. Goldman,, T. L. Doering,, L. Pirofski, and, A. Casadevall. 1999. Antibody response to Cryptococcus neoformans proteins in rodents and humans. Infect. Immun. 67:2218–2224.
35. Chong, Y.,, H. Ikematsu,, K. Kikuchi,, M. Yamamoto,, M. Murata,, M. Nishimura,, S. Nabeshima,, S. Kashiwagi, and, J. Hayashi. 2004. Selective CD27+ (memory) B cell reduction and characteristic B cell alteration in drug-naive and HAART-treated HIV type 1-infected patients. AIDS Res. Hum. Retroviruses 20:219–226.
36. Clatworthy, M. R., and, K. G. Smith. 2004. FcgammaRIIb balances efficient pathogen clearance and the cytokine-mediated consequences of sepsis. J. Exp. Med. 199:717–723.
37. Cleare, W., and, A. Casadevall. 1998. The different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays. Clin. Diagn. Lab. Immunol. 5:125–129.
38. Cooper, L. J.,, D. Robertson,, R. Granzow, and, N. S. Greenspan. 1994. Variable domain-identical antibodies exhibit IgG subclass-related differences in affinity and kinetic constants as determined by surface plasmon resonance. Mol. Immunol. 31:577–584.
39. Cooper, L. J.,, A. R. Shikhman,, D. D. Glass,, D. Kangisser,, M. W. Cunningham, and, N. S. Greenspan. 1993. Role of heavy chain constant domains in antibody-antigen interaction. Apparent specificity differences among streptococcal IgG antibodies expressing identical variable domains. J. Immunol. 150:2231–2242.
40. Cunto-Amesty, G.,, P. Luo,, B. Monzavi-Karbassi,, A. Lees,, J. Alexander,, M. F. del Guercio,, M. H. Nahm,, C. Artaud,, J. Stanley, and, T. Kieber-Emmons. 2003. Peptide mimotopes as prototypic templates of broad-spectrum surrogates of carbohydrate antigens. Cell Mol. Biol. 49:245–254.
41. Currie, B. P., and, A. Casadevall. 1994. Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin. Infect. Dis. 19:1029–1033.
42. Dammers, P. M., and, F. G. Kroese. 2001. Evolutionary relationship between rat and mouse immunoglobulin IGHV5 subgroup genes (PC7183) and human IGHV3 subgroup genes. Immunogenetics 53:511–517.
43. Davidkova, G.,, S. Pettersson,, D. Holmberg, and, I. Lundkvist. 1997. Selective usage of VH genes in adult human B lymphocyte repertoires. Scand. J. Immunol. 45:62–73.
44. De Bernardis, F.,, M. Boccanera,, D. Adriani,, A. Girolamo, and, A. Cassone. 2002. Intravaginal and intranasal immunizations are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis. Infect. Immun. 70:2725–2729.
45. De Bernardis, F.,, M. Boccanera,, D. Adriani,, E. Spreghini,, G. Santoni, and, A. Cassone. 1997. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect. Immun. 65:3399–3405.
46. DeShaw, M., and, L. Pirofski. 1995. Antibodies to Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan are ubiquitous in the serum of HIV+ and HIV- individuals. Clin. Exp. Immunol. 99:425–432.
47. Devi, S. G. N.,, R. Schneerson,, W. Egan,, T. J. Ulrich,, D. Bryla,, J. B. Robbins, and, J. E. Bennett. 1991. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect. Immun. 59:3700–3707.
48. Devi, S. J. 1996. Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Vaccine 14:841–844.
49. Dromer, F.,, P. Aucouturier,, J.-P. Clauvel,, G. Saimot, and, P. Yeni. 1988. Cryptococcus neoformans antibody levels in patients with AIDS. Scand. J. Infect. Dis. 20:283–285.
50. Dromer, F., and, J. Charreire. 1991. Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J. Infect. Dis. 163:1114–1120.
51. Dromer, F.,, J. Charreire,, A. Contrepois,, C. Carbon, and, P. Yeni. 1987. Protection of mice against experimental cryptococcosis by an anti-Cryptococcus neoformans monoclonal antibody. Infect. Immun. 55:749–752.
52. Dromer, F.,, C. Perronne,, J. Barge,, J. L. Vilde, and, P. Yeni. 1989. Role of IgG and complement component C5 in the initial course of experimental cryptococcosis. Clin. Exp. Immunol. 78:412–417.
53. Dromer, F.,, J. Salamero,, A. Contrepois,, C. Carbon, and, P. Yeni. 1987. Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide. Infect. Immun. 55:742–748.
54. Duro, R. M.,, D. Netski,, P. Thorkildson, and, T. R. Kozel. 2003. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan. Clin. Diagn. Lab. Immunol. 10:252–258.
55. Elvin, K.,, A. Bjorkman,, N. Heurlin,, B. M. Eriksson,, L. Barkholt, and, E. Linder. 1994. Seroreactivity to Pneumocystis carinii in patients with AIDS versus other immunosuppressed patients. Scand. J. Infect. Dis. 26:33–40.
56. Feldmesser, M.,, A. Mednick, and, A. Casadevall. 2002. Antibody-mediated protection in murine Cryptococcus neoformans infection is associated with pleotrophic effects on cytokine and leukocyte responses. Infect. Immun. 70:1571–1580.
57. Fernandez-Arenas, E.,, G. Molero,, C. Nombela,, R. Diez-Orejas, and, C. Gil. 2004. Contribution of the antibodies response induced by a low virulent Candida albicans strain in protection against systemic candidiasis. Proteomics 4:1204–1215.
58. Fleuridor, R.,, A. Lees, and, L. Pirofski. 2001. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection. J. Immunol. 166:1087–1096.
59. Fleuridor, R.,, R. H. Lyles, and, L. Pirofski. 1999. Quantitative and qualitative differences in the serum antibody profiles of HIV-infected persons with and without Cryptococcus neoformans meningitis. J. Infect. Dis. 180:1526–1536.
60. Fleuridor, R.,, Z. Zhong, and, L. Pirofski. 1998. A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis. J. Infect. Dis. 178:1213–1216.
61. French, N.,, K. Gray,, C. Watera,, J. Nakiyingi,, E. Lugada,, M. Moore,, D. Lalloo,, J. A. Whitworth, and, C. F. Gilks. 2002. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 16:1031–1038.
62. Fries, B. C.,, C. P. Taborda,, E. Serfass, and, A. Casadevall. 2001. Phenotypic switching of Cryptococcus neofor-mans occurs in vivo and influences the outcome of infection. J. Clin. Investig. 108:1639–1648.
63. Gigliotti, F., and, C. G. Haidaris. 1998. Antigenic characterization of Pneumocystis carinii. Semin. Respir. Infect. 13:313–322.
64. Gigliotti, F.,, C. G. Haidaris,, T. W. Wright, and, A. G. Harmsen. 2002. Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia. Infect. Immun. 70:1069–1074.
65. Gigliotti, F., and, A. G. Harmsen. 1997. Pneumocystis carinii host origin defines the antibody specificity and protective response induced by immunization. J. Infect. Dis. 176:1322–1326.
66. Gigliotti, F., and, W. T. Hughes. 1988. Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models. J. Clin. Investig. 81:1666–1668.
67. (Reference deleted.)
68. Gigliotti, F.,, D. C. Stokes,, A. B. Cheatham,, D. S. Davis, and, W. T. Hughes. 1986. Development of murine monoclonal antibodies to Pneumocystis carinii. J. Infect. Dis. 154:315–322.
69. Gigliotti, F.,, J. A. Wiley, and, A. G. Harmsen. 1998. Immunization with Pneumocystis carinii gpA is immunogenic but not protective in a mouse model of P. carinii pneumonia. Infect. Immun. 66:3179–3182.
70. Goldman, D. L.,, H. Khine,, J. Abadi,, D. L. Lindenberg,, L. Pirofski,, R. Niang, and, A. Casadevall. 2001. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 107:e66.
71. Gordon, M. A., and, E. Lapa. 1964. Serum protein enhancement of antibiotic therapy in cryptococcosis. J. Infect. Dis. 114:373–377.
72. Goren, M. B., and, G. M. Middlebrook. 1967. Protein conjugates of polysaccharide from Cryptococcus neofor-mans. J. Immunol. 98:901.
73. Grothaus, M. C.,, N. Srivastava,, S. L. Smithson,, T. Kieber-Emmons,, D. B. Williams,, G. M. Carlone, and, M. A. J. Westerink. 2000. Selection of an immunogenic peptide mimic of the capsular polysaccharide of Neisseria meningitidis serogroup A using a peptide display library. Vaccine 18:1253–1263.
74. Han, Y., and, J. E. Cutler. 1995. Antibody response that protects against disseminated candidiasis. Infect. Immun. 63:2714–2719.
75. Han, Y.,, T. R. Kozel,, M. X. Zhang,, R. S. MacGill,, M. C. Carroll, and, J. E. Cutler. 2001. Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis. J. Immunol. 167:1550–1557.
76. Han, Y.,, R. P. Morrison, and, J. E. Cutler. 1998. A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect. Immun. 66:5771–5776.
77. Han, Y.,, M. H. Riesselman, and, J. E. Cutler. 2000. Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody. Infect. Immun. 68:1649–1654.
78. Hardy, A. M.,, C. P. Wajszczuk,, A. F. Suffredini,, T. R. Hakala, and, M. Ho. 1984. Pneumocystis carinii pneumonia in renal-transplant recipients treated with cyclosporine and steroids. J. Infect. Dis. 149:143–147.
79. Harmsen, A. G., and, M. Stankiewicz. 1991. T cells are not sufficient for resistance to Pneumocystis carinii pneumonia in mice. J. Protozool. 38:44S–45S.
80. Harris, R. E.,, J. A. McCallister,, S. A. Allen,, A. S. Barton, and, R. L. Baehner. 1980. Prevention of pneumocystis pneumonia. Use of continuous sulfamethoxazoletrimethroprim therapy. Am. J. Dis. Child. 134:35–38.
81. Houpt, D. C.,, G. S. Pfrommer,, B. J. Young,, T. A. Larson, and, T. R. Kozel. 1994. Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan. Infect. Immun. 62:2857–2864.
82. Jo, E. K.,, H. S. Kim,, M. Y. Lee,, M. Iseki,, J. H. Lee,, C. H. Song,, J. K. Park,, T. J. Hwang, and, H. Kook. 2002. X-linked hyper-IgM syndrome associated with Cryptosporidium parvum and Cryptococcus neoformans infections: the first case with molecular diagnosis in Korea. J. Korean Med. Sci. 17:116–120.
83. Kagaya, K.,, Y. Miyakawa,, H. Fujihara,, M. Suzuki,, G. Soe, and, Y. Fukazawa. 1989. Immunologic significance of diverse specificity of monoclonal antibodies against mannans of Candida albicans. J. Immunol. 143:3353–3358.
84. Kanbe, T.,, Y. Han,, B. Redgrave,, M. H. Riesselman, and, J. E. Cutler. 1993. Evidence that mannans of Candida albicans are responsible for adherence of yeast forms to spleen and lymph node tissue. Infect. Immun. 61:2578–2584.
85. Kirkham, P. M.,, R. F. Mortari,, J. A. Newton, and, H. W. Schroeder. 1992. Immunoglobulin VH clan and family identity predicts variable domain structure and may influence antigen binding. EMBO J. 11:603–609.
86. Kozel, T. R.,, R. S. MacGill,, A. Percival, and, Q. Zhou. 2004. Biological activities of naturally occurring antibodies reactive with Candida albicans mannan. Infect. Immun. 72:209–218.
87. Kozel, T. R., and, T. G. McGaw. 1979. Opsonization of Cryptococcus neoformans by human immunoglobulin G: role of immunoglobulin G in phagocytosis by macrophages. Infect. Immun. 18:701–707.
88. Kruetzmann, S.,, M. M. Rosado,, H. Weber,, U. Germing,, O. Tournilhac,, H. H. Peter,, R. Berner,, A. Peters,, T. Boehm,, A. Plebani,, I. Quinti, and, R. Carsetti. 2003. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J. Exp. Med. 197:939–945.
89. Larsen, R. A.,, P. G. Pappas,, J. R. Perfect,, J. A. Aberg,, A. Casadevall,, G. A. Cloud,, R. James,, S. Filler,, W. E. Dismukes, and the National Institute of Allergy and Infectious Diseases Mycoses Study Group. 2005. Phase I evaluation of the safety and pharmacodynamic activity of a murine derived anti-cryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antmicrob. Agents Chemother. 49:952–958.
90. Laursen, A. L., and, P. L. Andersen. 1998. Low levels of IgG antibodies against Pneumocystis carinii among HIV-infected patients. Scand. J. Infect. Dis. 30:495–499.
91. Lesinski, G. B.,, S. L. Smithson,, N. Srivastava,, D. Chen,, G. Widera, and, M. A. Westerink. 2001. A DNA vaccine encoding a peptide mimic of Streptococcus pneumoniae serotype 4 capsular polysaccharide induces specific anti-carbohydrate antibodies in Balb/c mice. Vaccine 19:1717–1726.
92. Lund, F. E.,, K. Schuer,, M. Hollifield,, T. D. Randall, and, B. A. Garvy. 2003. Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P. carinii-specific antibody. J. Immunol. 171:1423–1430.
93. Lundgren, B.,, J. D. Lundgren,, T. Nielsen,, L. Mathiesen,, J. O. Nielsen, and, J. A. Kovacs. 1992. Antibody responses to a major Pneumocystis carinii antigen in human immunodeficiency virus-infected patients with and without P. carinii pneumonia. J. Infect. Dis. 165:1151–1155.
94. Magliani, W.,, S. Conti,, S. Arseni,, R. Frazzi,, A. Salati, and, L. Polonelli. 2001. Killer anti-idiotypes in the control of fungal infections. Curr. Opin. Investig. Drugs 2:477–479.
95. Magliani, W.,, S. Conti,, A. Salati,, S. Arseni,, L. Ravanetti,, R. Frazzi, and, L. Polonelli. 2003. Biotechnological approaches to the production of idiotypic vaccines and antiidiotypic antibiotics. Curr. Pharm. Biotechnol. 4:91–97.
96. Maitta, R.,, K. Datta,, Q. Chang,, R. Luo,, K. Subramaniam,, B. Witover, and, L. Pirofski. 2004. Protective and non-protective human IgM monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificity and gene use. Infect. Immun. 72:4810–4818.
97. Maitta, R.,, K. Datta, and, L. Pirofski. 2004. Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan. Vaccine 22/28–29:4062–4068.
98. Maitta, R. W.,, K. Datta,, A. Lees,, S. S. Belouski, and, L. A. Pirofski. 2004. Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice. Infect. Immun. 72:196–208.
99. Malbran, A.,, L. Belmonte,, B. Ruibal-Ares,, P. Bare,, I. Massud,, C. Parodi,, M. Felippo,, R. Hodinka,, K. Haines,, K. E. Nichols, and, M. M. de Bracco. 2004. Loss of circulating CD27+ memory B cells and CCR4+ T cells occurring in association with elevated EBV loads in XLP patients surviving primary EBV infection. Blood 103:1625–1631.
100. Marcotte, H.,, D. Levesque,, K. Delanay,, A. Bourgeault,, R. de la Durantaye,, S. Brochu, and, M. C. Lavoie. 1996. Pneumocystis carinii infection in transgenic B cell-deficient mice. J. Infect. Dis. 173:1034–1037.
101. Marquis, G.,, S. Montplaisir,, M. Pelletier,, S. Mousseau, and, P. Auger. 1985. Genetic resistance to murine cryptococcosis: increased susceptibility in the CBA/N XID mutant strain of mice. Infect. Immun. 47:282–287.
102. Marshall, E. 1995. Dispute slows paper on “remarkable” vaccine. Science 268:1712–1715.
103. Marten, N. W.,, S. A. Stohlman, and, C. C. Bergmann. 2001. MHV infection of the CNS: mechanisms of immune-mediated control. Viral Immunol. 14:1–18.
104. Martinez, L. R.,, D. Moussai, and, A. Casadevall. 2004. Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen. Infect. Immun. 72:3674–3679.
105. Matthews, R., and, J. Burnie. 1989. Cloning of a DNA sequence encoding a major fragment of the 47 kilodalton stress protein homologue of Candida albicans. FEMS Microbiol. Lett. 51:25–30.
106. Matthews, R.,, J. Burnie,, D. Smith,, I. Clark,, J. Midgley,, M. Conolly, and, B. Gazzard. 1988. Candida and AIDS: evidence for protective antibody. Lancet ii:263–266.
107. Matthews, R.,, J. P. Burnie, and, W. Lee. 1991. The application of epitope mapping in the development of a new serological test for systemic candidosis. J. Immunol. Methods 143:73–79.
108. Matthews, R.,, S. Hodgetts, and, J. Burnie. 1995. Preliminary assessment of a human recombinant antibody fragment to hsp90 in murine invasive candidiasis. J. Infect. Dis. 171:1668–1671.
109. Matthews, R.,, C. Wells, and, J. P. Burnie. 1988. Characterisation and cellular localisation of the immunodominant 47-kda antigen of Candida albicans. J. Med. Microbiol. 27:227–232.
110. Matthews, R. C.,, J. P. Burnie,, D. Howat,, T. Rowland, and, F. Walton. 1991. Autoantibody to heat-shock protein 90 can mediate protection against systemic candidosis. Immunology 74:20–24.
111. Matthews, R. C.,, J. P. Burnie, and, S. Tabaqchali. 1984. Immunoblot analysis of the serological response in systemic candidosis. Lancet ii:1415–1418.
112. Matthews, R. C.,, J. P. Burnie, and, S. Tabaqchali. 1987. Isolation of immunodominant antigens from sera of patients with systemic candidiasis and characterization of serological response to Candida albicans. J. Clin. Microbiol. 25:230–237.
113. Matthews, R. C.,, G. Rigg,, S. Hodgetts,, T. Carter,, C. Chapman,, C. Gregory,, C. Illidge, and, J. Burnie. 2003. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob. Agents Chemother. 47:2208–2216.
114. May, R. J.,, D. O. Beenhouwer, and, M. D. Scharff. 2003. Antibodies to keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates: implications for vaccine development. J. Immunol. 171:4905–4912.
115. McGaw, T. G., and, T. R. Kozel. 1979. Opsonization of Cryptococcus neoformans by human immunoglobulin G: masking of immunoglobulin G by cryptococcal polysaccharide. Infect. Immun. 25:262–267.
116. McLean, G. R.,, M. Torres,, N. Elguezabal,, A. Nakouzi, and, A. Casadevall. 2002. Isotype can affect the fine specificity of an antibody for a polysaccharide antigen. J. Immunol. 169:1379–1386.
117. Mednick, A. J.,, M. Feldmesser,, J. Rivera, and, A. Casadevall. 2003. Neutropenia alters lung cytokine production in mice and reduces their susceptibility to pulmonary cryptococcosis. Eur. J. Immunol. 33:1744–1753.
118. Miyakawa, Y.,, K. Kagaya,, Y. Fukazawa, and, G. Soe. 1986. Production and characterization of agglutinating monoclonal antibodies against predominant antigenic factors for Candida albicans. J. Clin. Microbiol. 23:881–886.
119. Monari, C.,, A. Casadevall,, C. Retini,, F. Baldelli,, F. Bistoni, and, A. Vecchiarelli. 1999. Antibody to capsular polysaccharide enhances the function of neutrophils from patients with AIDS against Cryptococcus neoformans. AIDS 13:653–660.
120. Monga, D. P.,, R. Kumar,, L. N. Mohapatra, and, A. N. Malaviya. 1979. Experimental cryptococcosis in normal and B-cell-deficient mice. Infect. Immun. 26:1–3.
121. Montagnoli, C.,, S. Bozza,, A. Bacci,, R. Gaziano,, P. Mosci,, J. Morschhaauser,, L. Pitzurra,, M. Kopf,, J. Cutler, and, L. Romani. 2003. A role for antibodies in the generation of memory antifungal immunity. Eur. J. Immunol. 33:1183–1192.
122. Moragues, M. D.,, M. J. Omaetxebarria,, N. Elguezabal,, M. J. Sevilla,, S. Conti,, L. Polonelli, and, J. Ponton. 2003. A monoclonal antibody directed against a Candida albi-cans cell wall mannoprotein exerts three anti-C. albicans activities. Infect. Immun. 71:5273–5279.
123. Mozaffarian, N.,, J. W. Berman, and, A. Casadevall. 1995. Immune complexes increase nitric oxide production by interferon-gamma-stimulated murine macrophage-like J774.16 cells. J. Leukos. Biol. 57:657–662.
124. Mukherjee, J.,, A. Casadevall, and, M. D. Scharff. 1993. Molecular characterization of the antibody responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J. Exp. Med. 177:1105–1116.
125. Mukherjee, J.,, M. Feldmesser,, M. D. Scharff, and, A. Casadevall. 2000. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy. Antimicrob. Agents Chemother. 39:1398–1405.
126. Mukherjee, J.,, T. R. Kozel, and, A. Casadevall. 1998. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies. J. Immunol. 161:3557–3567.
127. Mukherjee, J.,, G. Nussbaum,, M. D. Scharff, and, A. Casadevall. 1995. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J. Exp. Med. 181:405–409.
128. Mukherjee, J.,, L. Pirofski,, M. D. Scharff, and, A. Casadevall. 1993. Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neofor-mans infection. Proc. Natl. Acad. Sci. USA 90:3636–3640.
129. Mukherjee, J.,, M. D. Scharff, and, A. Casadevall. 1992. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect. Immun. 60:4534–4541.
130. Mukherjee, J.,, M. D. Scharff, and, A. Casadevall. 1995. Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains. Infect. Immun. 63:3353–3359.
131. Mukherjee, J.,, L. S. Zuckier,, M. D. Scharff, and, A. Casadevall. 1994. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob. Agents Chemother. 38:580–587.
132. Mukherjee, S.,, S. Lee,, J. Mukherjee,, M. D. Scharff, and, A. Casadevall. 1994. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect. Immun. 62:1079–1088.
133. Mukherjee, S.,, S. C. Lee, and, A. Casadevall. 1995. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect. Immun. 63:573–579.
134. Nagase, H.,, K. Agematsu,, K. Kitano,, M. Takamoto,, Y. Okubo,, A. Komiyama, and, K. Sugane. 2001. Mechanism of hypergammaglobulinemia by HIV infection: circulating memory B-cell reduction with plasmacytosis. Clin. Immunol. 100:250–259.
135. Nakouzi, A., and, A. Casadevall. 2003. The function of conserved amino acids in or near the complementarity determining regions for related antibodies to Cryptococcus neoformans glucuronoxylomannan. Mol. Immunol. 40:351–361.
136. Nakouzi, A.,, P. Valadon,, J. D. Nosanchuk,, N. Green, and, A. Casadevall. 2001. Molecular basis for immunoglobulin M specificity to epitopes in Cryptococcus neoformans polysaccharide that elicit protective and non-protective antibodies. Infect. Immun. 69:3398–3409.
137. Netski, D., and, T. R. Kozel. 2002. Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity. Infect. Immun. 70:2812–2819.
138. Nooney, L.,, R. C. Matthews, and, J. P. Burnie. 2005. Evaluation of Mycograb(R), amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Diagn. Microbiol. Infect. Dis. 51:19–29.
139. Nosanchuk, J. D.,, A. L. Rosas, and, A. Casadevall. 1998. The antibody response to fungal melanin in mice. J. Immunol. 160:6026–6031.
140. Nosanchuk, J. D.,, J. N. Steenbergen,, L. Shi,, G. S. Deepe, Jr., and, A. Casadevall. 2003. Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum. J. Clin. Investig. 112:1164–1175.
141. Nussbaum, G.,, W. Cleare,, A. Casadevall,, M. D. Scharff, and, P. Valadon. 1997. Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J. Exp. Med. 185:685–694.
142. Nussbaum, G.,, R. Yuan,, A. Casadevall, and, M. D. Scharff. 1996. Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans. J. Exp. Med. 183:1905–1909.
143. Pascale, J. M.,, M. M. Shaw,, P. J. Durant,, A. A. Amador,, M. S. Bartlett,, J. W. Smith,, R. L. Gregory, and, G. L. McLaughlin. 1999. Intranasal immunization confers protection against murine Pneumocystis carinii lung infection. Infect. Immun. 67:805–809.
144. Pifer, L. L.,, W. T. Hughes,, S. Stagno, and, D. Woods. 1978. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics 61:35–41.
145. Pirofski, L. 2001. Polysaccharides, mimotopes and vaccines for encapsulated pathogens. Trends Microbiol. 9:445–452.
146. Pirofski, L., and, A. Casadevall. 1996. Cryptococcus neoformans : paradigm for the role of antibody in immunity. Zentbl. Bakteriol. 284:475–495.
147. Pirofski, L.,, R. Lui,, M. DeShaw,, A. B. Kressel, and, Z. Zhong. 1995. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine. Infect. Immun. 63:3005–3014.
148. Pitzurra, L.,, S. Perito,, F. Baldelli,, F. Bistoni, and, A. Vecchiarelli. 2003. Humoral response against Cryptococcus neoformans mannoprotein antigens in HIV-infected patients. Clin. Exp. Immunol. 133:91–96.
149. Polonelli, L. 2000. Human, monoclonal and recombinant candidacidal, pneumocysticidal and mycobactericidal antibodies. Indian J. Chest Dis. Allied Sci. 42:259–263.
150. Polonelli, L.,, F. De Bernadis,, S. Conti,, M. Boccanera,, W. Magliani,, M. Gerloni,, C. Cantelli, and, A. Cassone. 1996. Human natural yeast killer toxinlike candidacidal antibodies. J. Immunol. 156:1880–1885.
151. Polonelli, L.,, F. De Bernardis,, S. Conti,, M. Boccanera,, M. Gerloni,, G. Morace,, W. Magliani,, C. Chezzi, and, A. Cassone. 1994. Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies. J. Immunol. 152:3175–3182.
152. Polonelli, L.,, R. Lorenzini,, F. De Bernardis,, M. Gerloni,, S. Conti,, G. Morace,, W. Magliani, and, C. Chezzi. 1993. Idiotypic vaccination: immunoprotection mediated by anti-idiotypic antibodies with antibiotic activity. Scand. J. Immunol. 37:105–110.
153. Polonelli, L.,, W. Magliani,, S. Conti,, L. Bracci,, L. Lozzi,, P. Neri,, D. Adriani,, F. De Bernardis, and, A. Cassone. 2003. Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infect. Immun. 71:6205–6212.
154. Polonelli, L., and, G. Morace. 1987. Production and characterization of yeast killer toxin monoclonal antibodies. J. Clin. Microbiol. 25:460–462.
155. Polonelli, L., and, G. Morace. 1988. Yeast killer toxin-like anti-idiotypic antibodies. J. Clin. Microbiol. 26:602–604.
156. Porsius, J. C.,, H. J. van Vliet,, J. H. van Zeijl,, W. H. Goessens, and, M. F. Michel. 1990. Detection of an antibody response in immunocompetent patients with systemic candidiasis or Candida albicans colonisation. Eur. J. Clin. Microbiol. Infect. Dis. 9:352–355.
157. Ramakrishna, C.,, S. A. Stohlman,, R. D. Atkinson,, M. J. Shlomchik, and, C. C. Bergmann. 2002. Mechanisms of central nervous system viral persistence: the critical role of antibody and B cells. J. Immunol. 168:1204–1211.
158. Retini, C.,, A. Casadevall,, D. Pietrella,, C. Monari,, B. Palazzetti, and, A. Vecchiarelli. 1999. Specific activated T cells regulate IL-12 production by human monocytes stimulated with Cryptococcus neoformans. J. Immunol. 162:1618–1623.
159. Rivera, J.,, J. Mukherjee,, L. M. Weiss, and, A. Casadevall. 2002. Antibody efficacy in murine pulmonary Cryptococcus neoformans infection: a role for nitric oxide. J. Immunol. 168:3419–3427.
160. Rivera, J.,, O. Zaragoza, and, A. Casadevall. 2005. Antibody-mediated protection against Cryptococcus neoformans is dependent on B cells. Infect. Immun. 73:1141–1150.
161. Robbins, J. B.,, R. Schneerson, and, S. C. Szu. 1995. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 171:1387–1398.
162. Rodrigues, M. L.,, L. R. Travassos,, K. R. Miranda,, A. J. Franzen,, S. Rozental,, W. de Souza,, C. S. Alviano, and, E. Barreto-Bergter. 2000. Human antibodies against a purified glucosylceramide from Cryptococcus neoformans inhibit cell budding and fungal growth. Infect. Immun. 68:7049–7060.
163. Rosas, A. L.,, J. D. Nosanchuk, and, A. Casadevall. 2001. Passive immunization with melanin-binding monoclonal antibodies prolongs survival of mice with lethal Cryptococcus neoformans infection. Infect. Immun. 69:3410–3412.
164. San Millan, R.,, N. Elguezabal,, P. Regulez,, M. D. Moragues,, G. Quindos, and, J. Ponton. 2000. Effect of salivary secretory IgA on the adhesion of Candida albi-cans to polystyrene. Microbiology 146:2105–2112.
165. San Millan, R.,, P. A. Ezkurra,, G. Quindos,, R. Robert,, J. M. Senet, and, J. Ponton. 1996. Effect of monoclonal antibodies directed against Candida albicans cell wall antigens on the adhesion of the fungus to polystyrene. Microbiology 142:2271–2277.
166. Scamurra, R. W.,, D. J. Miller,, M. Abrahamsen,, V. Kapur,, S. M. Wahl,, E. C. Milner, and, E. N. Janoff. 2000. Impact of HIV-1 infection on VH3 gene repertoire of naive human B cells. J. Immunol. 164:5482–5491.
167. Schlageter, A. M., and, T. R. Kozel. 1990. Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide. Infect. Immun. 58:1914–1918.
168. Seguy, N.,, L. Polonelli,, E. Dei-Cas, and, J. C. Cailliez. 1998. Effect of a killer toxin of Pichia anomala to Pneumocystis. Perspectives in the control of pneumocystosis. FEMS Immunol. Med. Microbiol. 22:145–149.
169. Shapiro, S.,, D. O. Beenhouwer,, M. Feldmesser,, C. Taborda,, M. C. Carroll,, A. Casadevall, and, M. D. Scharff. 2002. Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3. Infect. Immun. 70:2598–2604.
170. Shen, H.,, J. K. Whitmire,, X. Fan,, D. J. Shedlock,, S. M. Kaech, and, R. Ahmed. 2003. A specific role for B cells in the generation of CD8 T cell memory by recombinant Listeria monocytogenes. J. Immunol. 170:1443–1451.
171. Shin, J. S.,, J. Yu,, J. Lin,, L. Zhong,, K. L. Bren, and, M. H. Nahm. 2002. Peptide mimotopes of pneumococcal capsular polysaccharide of 6B serotype: a peptide mimotope can bind to two unrelated antibodies. J. Immunol. 168:6273–6278.
172. Sinha, B. K.,, S. Prasad, and, D. P. Monga. 1987. Studies of the role of B-cells in the resistance of mice to experimental candidiasis. Zentbl. Bakteriol. Mikrobiol. Hyg. Ser. A 266:316–322.
173. Speed, B. R.,, J. Kaldor,, B. Cairns, and, M. Pegorer. 1996. Serum antibody response to active infection with Cryptococcus neoformans and its varieties in immuno-competent subjects. J. Med. Vet. Mycol. 34:187–193.
174. Sundstrom, J. B., and, R. Cherniak. 1992. The glucuronoxylomannan of Cryptococcus neoformans serotype A is a type 2 T-cell-independent antigen. Infect. Immun. 60:4080–4087.
175. Swoboda, R. K.,, G. Bertram,, S. Budge,, G. W. Gooday,, N. A. Gow, and, A. J. Brown. 1995. Structure and regulation of the HSP90 gene from the pathogenic fungus Candida albicans. Infect. Immun. 63:4506–4514.
176. Syme, R. M.,, J. C. Spurrell,, E. K. Amankwah,, F. H. Green, and, C. H. Mody. 2002. Primary dendritic cells phagocytose Cryptococcus neoformans via mannose receptors and Fc³ receptor II for presentation to T lymphocytes. Infect. Immun. 70:5972–5981.
177. Tabone, M. D.,, G. Leverger,, J. Landman,, C. Aznar,, L. Boccon-Gibon, and, G. Lasfargues. 1994. Disseminated lymphonodular cryptococcosis in a child with X-linked hyper-IgM immunodeficiency. Pediatr. Infect. Dis. J. 13:77–79.
178. Taborda, C., and, A. Casadevall. 2001. Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments. J. Immunol. 166:2100–2107.
179. Taborda, C.,, J. Rivera,, O. Zaragoza, and, A. Casadevall. 2003. More is not necessarily better: prozone-like effects in passive immunization with IgG. J. Immunol. 170:3621–3620.
180. Taborda, C. P., and, A. Casadevall. 2002. CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are involved in complement-independent antibody-mediated phagocytosis of Cryptococcus neoformans. Immunity 16:791–802.
181. Tavares, D.,, P. Ferreira,, M. Vilanova,, A. Videira, and, M. Arala-Chaves. 1995. Immunoprotection against systemic candidiasis in mice. Int. Immunol. 7:785–796.
182. Torres, M.,, R. May,, M. D. Scharff, and, A. Casadevall. 2005. Variable-region identical antibodies differing in isotype demonstrate differences in fine specificity and idiotype. J. Immunol. 174:2132–2142.
183. Travassos, L. R.,, L. S. Silva,, E. G. Rodrigues,, S. Conti,, A. Salati,, W. Magliani, and, L. Polonelli. 2004. Therapeutic activity of a killer peptide against experimental paracoccidioidomycosis. J. Antimicrob. Chemother. 54:956–958.
184. Valadon, P.,, G. Nussbaum,, L. F. Boyd,, D. H. Margulies, and, M. D. Scharff. 1996. Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans. J. Mol. Biol. 261:11–22.
185. Valadon, P.,, G. Nussbaum,, J. Oh, and, M. D. Scharff. 1998. Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide. J. Immunol. 161:1829–1836.
186. van de Moer, A.,, S. L. Salhi,, R. Cherniak,, B. Pau,, M. L. Garrigues, and, J. M. Bastide. 1990. An anti-Cryptococcus neoformans monoclonal antibody directed against galactoxylomannan. Res. Immunol. 141:33–42.
187. van Deventer, H. J.,, W. H. Goessens,, A. J. van Vliet, and, H. A. Verbrugh. 1996. Anti-enolase antibodies partially protective against systemic candidiasis in mice. Clin. Microbiol. Infect. 2:36–43.
188. Vargas-Madrazo, E.,, F. Lara-Ochoa, and, J. C. Almagro. 1995. Canonical structure repertoire of the antigen-binding site of immunoglobulins suggests strong geometrical restrictions associated to the mechanism of immune recognition. J. Mol. Biol. 254:497–504.
189. Vecchiarelli, A.,, C. Monari,, C. Retini,, D. Pietrella,, B. Palazzetti,, L. Pitzurra, and, A. Casadevall. 1998. Cryptococcus neoformans differently regulates B7-1 (CD80) and B7-2 (CD86) expression on human monocytes. Eur. J. Immunol. 28:114–121.
190. Vecchiarelli, A.,, D. Pietrella,, F. Bistoni,, T. R. Kozel, and, A. Casadevall. 2002. Antibody to Cryptococcus neofor-mans capsular glucuronoxylomannan promotes expression of interleukin-12Rbeta2 subunit on human T cells in vitro through effects mediated by antigen-presenting cells. Immunology 106:267–272.
191. Vecchiarelli, A.,, C. Retini,, A. Casadevall,, C. Monari,, D. Pietrella, and, T. R. Kozel. 1998. Involvement of C3a and C5a in interleukin-8 secretion by human polymorphonuclear cells in response to capsular material of Cryptococcus neoformans. Infect. Immun. 66:4324–4330.
192. Vecchiarelli, A.,, C. Retini,, C. Monari, and, A. Casadevall. 1998. Specific antibody to Cryptococcus neoformans alters human leukocyte cytokine synthesis and promotes T-cell proliferation. Infect. Immun. 66:1244–1247.
193. Vilanova, M.,, L. Teixeira,, I. Caramalho,, E. Torrado,, A. Marques,, P. Madureira,, A. Ribeiro,, P. Ferreira,, M. Gama, and, J. Demengeot. 2004. Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2. Immunology 111:334–342.
194. Viudes, A.,, A. Lazzell,, S. Perea,, W. R. Kirkpatrick,, J. Peman,, T. F. Patterson,, J. P. Martinez, and, J. L. Lopez-Ribot. 2004. The C-terminal antibody binding domain of Candida albicans mp58 represents a protective epitope during candidiasis. FEMS Microbiol. Lett. 232:133–138.
195. Weller, S.,, M. C. Braun,, B. K. Tan,, A. Rosenwald,, C. Cordier,, M. E. Conley,, A. Plebani,, D. S. Kumararatne,, D. Bonnet,, O. Tournilhac,, G. Tchernia,, B. Steiniger,, L. M. Staudt,, J. L. Casanova,, C. A. Reynaud, and, J. C. Weill. 2004. Human blood IgM “memory” B cells are circulating splenic marginal zone B cells harboring a pre-diversified immunoglobulin repertoire. Blood. 104:3647–3654.
196. Wellington, M.,, J. M. Bliss, and, C. G. Haidaris. 2003. Enhanced phagocytosis of Candida species mediated by opsonization with a recombinant human antibody single-chain variable fragment. Infect. Immun. 71:7228–7231.
197. Wells, J.,, F. Gigliotti,, P. J. Simpson-Haidaris, and, C. G. Haidaris. 2004. Epitope mapping of a protective monoclonal antibody against Pneumocystis carinii with shared reactivity to Streptococcus pneumoniae surface antigen PspA. Infect. Immun. 72:1548–1556.
198. Wilson, M. A., and, T. R. Kozel. 1992. Contribution of antibody in normal human serum to early deposition of C3 onto encapsulated and nonencapsulated Cryptococcus neoformans. Infect. Immun. 60:754–761.
199. Winkelstein, J. A.,, M. C. Marino,, H. Ochs,, R. Fuleihan,, P. R. Scholl,, R. Geha,, E. R. Stiehm, and, M. E. Conley. 2003. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine 82:373–384.
200. Wuthrich, M., and, B. S. Klein. 2000. Investigation of anti-WI-1 adhesin antibody-mediated protection in experimental pulmonary blastomycosis. J. Infect. Dis. 181:1720–1728.
201. Xu, J. L., and, M. M. Davis. 2000. Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity 13:37–45.
202. Young, A. C.,, P. Valadon,, A. Casadevall,, M. D. Scharff, and, J. C. Sacchettini. 1997. The three dimensional structures of a polysaccharide binding antibody to Cryptococcus neoformans and its complex with a peptide from a phage library: implications for the identification of peptide mimotopes. J. Mol. Biol. 74:22–34.
203. Yuan, R.,, A. Casadevall, and, M. D. Scharff. 1997. T cells cooperate with passive antibody to modify the course of Cryptococcus neoformans in mice. Proc. Natl. Acad. Sci. USA 94:2483–2488.
204. Zhang, H.,, Z. Zhong, and, L. Pirofski. 1997. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody. Infect. Immun. 65:1158–1164.
205. Zhang, M. X.,, J. E. Cutler,, Y. Han, and, T. R. Kozel. 1998. Contrasting roles of mannan-specific monoclonal immunoglobulin M antibodies in the activation of classical and alternative pathways by Candida albicans. Infect. Immun. 66:6027–6029.
206. Zhang, M. X., and, T. R. Kozel. 1998. Mannan-specific immunoglobulin G antibodies in normal human serum accelerate binding of C3 to Candida albicans via the alternative complement pathway. Infect. Immun. 66:4845–4850.
207. Zhang, M. X.,, D. M. Lupan, and, T. R. Kozel. 1997. Mannan-specific immunoglobulin G antibodies in normal human serum mediate classical pathway initiation of C3 binding to Candida albicans. Infect. Immun. 65:3822–3827.
208. Zhong, Z., and, L. Pirofski. 1996. Opsonization of Cryptococcus neoformans by human anti-glucuronoxylomannan antibodies. Infect. Immun. 64:3446–3450.
209. Zhong, Z., and, L. Pirofski. 1998. Antifungal activity of a human antiglucuronoxylomannan antibody. Clin. Diagn. Lab. Immunol. 5:58–64.

Back to top
This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error